Steroid: Pharmacology

Since their identification nearly 80 years ago, steroids have played a prominent role in the treatment of many disease states. Many of the clinical roles of steroids are related to their potent antiinflammatory and immune-modulating properties…

Since their identification in 1935, steroids have served a wide range of uses. Initially, these isolates from adrenal glands were thought to be useful only in patients suffering from Addison disease. Today, many of the clinical roles of steroids are related to their potent antiinflammatory and immune-modulating properties. Clinically relevant side effects of steroids are common and problematic, ranging from a minor case of acne to Cushing syndrome that can result in diabetes mellitus and potentially life-threatening heart disease if untreated. Side effects can occur at a wide range of doses and vary depending on the route of administration.

The term steroid applies to a wide range of molecules with varying physiological effects. More specifically, corticosteroids are a class of chemicals encompassing both laboratory-synthesized and naturally produced hormones. Glucocorticoids, in general, regulate metabolism and inflammation; mineralocorticoids regulate sodium and water levels. Corticosteroids fall along a spectrum from exclusively glucocorticoid effects to exclusively mineralocorticoid effects, and steroid compounds are selected based on their appropriateness for a given treatment. For example, although a compound may possess potent antiinflammatory properties, it may additionally have mineralocorticoid activity that adversely affects blood pressure.

CORTICOSTEROID METABOLISM AND CLINICAL ROLE

Although corticosteroid metabolism is complicated by enzyme induction, protein binding, molecular interconversion, and interaction with endogenous cortisol, corticosteroids are generally metabolized by the hepatic P450 system. Direct application (eg, topical, intraarticular, inhaled, or epidural) of these agents to sites of inflammation bypasses the liver and its first-pass effect.

Chronic oral glucocorticoid use is common in patients with rheumatoid arthritis, chronic obstructive pulmonary disease, systemic lupus erythematosus, inflammatory bowel disease, and asthma. Side effects of chronic use include bruising, muscle weakness, weight gain, skin changes, sleep disturbances, cataracts, and pathologic fractures. Glucocorticoid administration can also have psychiatric side effects: mood disorders, anxiety, delirium, and panic disorder. Psychotropic medication may be required to treat these symptoms, but the prognosis is favorable once the glucocorticoids are reduced or discontinued. Adverse effects occur in up to 90% of patients who take glucocorticoids for >60 days. These side effects, including the more serious fractures and cataracts, occur even in patients taking low (≤7.5 mg/d) dosages.,

Glucocorticoids affect bone mineralization by inhibiting calcium absorption in the gastrointestinal tract and shifting signaling-molecule production to favor bone resorption. Recommendations for preventing glucocorticoid-induced osteopenia and its subsequent complications and comorbidities include supplementing calcium with vitamin D for glucocorticoid doses ≥5 mg/d and starting bisphosphonates when indicated by densiometric evaluation.

Because of their effects on insulin resistance, glucocorticoids are the most common cause of drug-induced diabetes mellitus. Screening guidelines using a fasting glucose ≥126 mg/dL or HbA1c ≥6.5% are suitable for diagnosing steroid-induced diabetes; however, per American Diabetes Association guidelines, results should be confirmed via repeat testing. Management is similar to that of type 2 diabetes mellitus; treatment options progress from single agent to double agent to insulin ± another agent, based upon fasting glucose measurements and glucose control. In patients with preexisting diabetes, blood sugars should be measured more often than in patients without preexisting diabetes, and medications should be adjusted to maintain adequate control.

Cushing syndrome and adrenal suppression have been observed in patients taking oral, intraarticular, epidural, inhaled, nasal, ocular, and topical glucocorticoid preparations., These side effects become more likely with longer durations of treatment and higher dosages.,

Mineralocorticoid activity causes the retention of sodium and free water and the excretion of potassium. Derangements in mineralocorticoid production can manifest with abnormalities in any of these areas. Hyponatremia, hyperkalemia, and hypotension are present to varying degrees in mineralocorticoid-deficient states (eg, various congenital adrenal hyperplasias and aldosterone synthase deficiency), whereas the inverse is present in mineralocorticoid-excess states (eg, Conn syndrome). Because endogenous glucocorticoids also have activity at mineralocorticoid receptors, signs and symptoms of mineralocorticoid excess can be seen in cases of excess glucocorticoid production (eg, Cushing syndrome).

The antiinflammatory properties of steroids have been attributed to their inhibitory effects on the action of phospholipase A2, an enzyme critical to the production of inflammatory compounds. Research has shown that steroids are active in affecting gene expression, translation, and enzyme activity. In short, they bring about their physiologic effects through a multitude of biochemical pathways. One such pathway is through their induction of the production of proteins called lipocortins. Glucocorticoids stem the production of inflammatory mediators such as leukotrienes and prostaglandins and effectively halt the inflammatory cascade., As their wide-ranging side effects indicate, glucocorticoids can impact many systems throughout the body. Through negative feedback regulation of the hypothalamic-pituitary-adrenal (HPA) axis, exogenous glucocorticoids can directly induce hypopituitarism (Addison disease)., Their actions on glucose metabolism can increase insulin resistance in tissues and increase fasting glucose levels., Glucocorticoids can act directly on osteoclasts to affect bone resorption and decrease calcium absorption in the gastrointestinal tract, resulting in osteopenia and osteoporosis., more »

This article meets the Accreditation Council for Graduate Medical Education and the American Board of Medical Specialties Maintenance of Certification competencies for Patient Care and Medical Knowledge.

REFERENCES

1. Kendall EC. Nobel lecture: The development of cortisone as a therapeutic agent. Nobelprize.org1950 December 11. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1950/kendall-lecture.html. Accessed March 10, 2013. []

2. Stewart PM, Krone NP. The adrenal cortex. In: Melmed S, Polonsky K, Larsen PR, Kronenberg H, editors. Williams Textbook of Endocrinology. 12th ed. Philadelphia, PA: Saunders;; 2011. In. eds. []

3. Xu J, Winkler J, Derendorf H. A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma. J Pharmacokinet Pharmacodyn2007 Jun;34(3):355–372. Epub 2007 Feb 23. [PubMed[]

1. Kendall EC. Nobel lecture: The development of cortisone as a therapeutic agent. Nobelprize.org. 1950 December 11. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1950/kendall-lecture.html. Accessed March 10, 2013. []
2. Stewart PM, Krone NP. The adrenal cortex. In: Melmed S, Polonsky K, Larsen PR, Kronenberg H, editors. Williams Textbook of Endocrinology. 12th ed. Philadelphia, PA: Saunders;; 2011. In. eds. []
3. Xu J, Winkler J, Derendorf H. A pharmacokinetic/pharmacodynamic approach to predict total prednisolone concentrations in human plasma. J Pharmacokinet Pharmacodyn. 2007 Jun;34(3):355–372. Epub 2007 Feb 23. [PubMed] []
4. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006 Jun 15;55(3):420–426. [PubMed] []
5. Kenna HA, Poon AW, de los Angeles CP, Koran LM. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011 Oct;65(6):549–560. [PubMed] []
6. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006 Oct;81(10):1361–1367. [PubMed] []
7. Patten SB, Neutel CI. Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. Drug Saf. 2000 Feb;22(2):111–122. [PubMed] []
8. Pereira RM, Carvalho JF, Canalis E. Glucocorticoid-induced osteoporosis in rheumatic diseases. Clinics (Sao Paulo) 2010;65(11):1197–1205. [PMC free article] [PubMed] []
9. Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med. 2011 Nov;78(11):748–756. [PubMed] []
10. Benzon HT, Gissen AJ, Strichartz GR, Avram MJ, Covino BG. The effect of polyethylene glycol on mammalian nerve impulses. Anesth Analg. 1987 Jun;66(6):553–559. [PubMed] []
11. Craig DB, Habib GG. Flaccid paraparesis following obstetrical epidural anesthesia: possible role of benzyl alcohol. Anesth Analg. 1977 Mar-Apr;56(2):219–221. [PubMed] []
12. Ahadian FM, McGreevy K, Schulteis G. Lumbar transforaminal epidural dexamethasone: a prospective, randomized, double-blind, dose-response trial. Reg Anesth Pain Med. 2011 Nov-Dec;36(6):572–578. [PubMed] []
13. Dreyfuss P, Baker R, Bogduk N. Comparative effectiveness of cervical transforaminal injections with particulate and nonparticulate corticosteroid preparations for cervical radicular pain. Pain Med. 2006 May-Jun;7(3):237–242. [PubMed] []
14. Somayaji HS, Saifuddin A, Casey AT, Briggs TW. Spinal cord infarction following therapeutic computed tomography-guided left L2 nerve root injection. Spine (Phila Pa 1976) 2005 Feb 15;30(4):E106–E108. [PubMed] []
15. McClain RW, Yentzer BA, Feldman SR. Comparison of skin concentrations following topical versus oral corticosteroid treatment: reconsidering the treatment of common inflammatory dermatoses. J Drugs Dermatol. 2009 Dec;8(12):1076–1079. [PubMed] []
16. Morley KW, Dinulos JG. Update on topical glucocorticoid use in children. Curr Opin Pediatr. 2012 Feb;24(1):121–128. [PubMed] []
17. Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 2012 Jan;67(1):35–41. Epub 2011 Aug 9. [PubMed] []
18. Doherty DE, Tashkin DP, Kerwin E, et al. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis. 2012; 7:57–71. Epub 2012 Feb 3. [PMC free article] [PubMed] []
19. Taplin CE, Cowell CT, Silink M, Ambler GR. Fludrocortisone therapy in cerebral salt wasting. Pediatrics. 2006 Dec;118(6):e1904–e1908. [PubMed] []
20. Freitas J, Santos R, Azevedo E, Costa O, Carvalho M, de Freitas AF. Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin Auton Res. 2000 Oct;10(5):293–299. [PubMed] []
21. Physicians Total Care, Inc. Fludrocortisone acetate tablet. Daily Med. 2010 September. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bf927cd9-1891-4de4-b4be-743a26363a64. Accessed April 1, 2014. []
22. Wallner BP, Mattaliano RJ, Hession C, et al. Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity. Nature. 1986 Mar 6-12;320(6057):77–81. [PubMed] []
23. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med. 2005 Oct 20;353(16):1711–1723. [PubMed] []
24. Blackwell GJ, Carnuccio R, Di Rosa M, Flower RJ, Parente L, Persico P. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature. 1980 Sep 11;287(5778):147–149. [PubMed] []
25. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003 Feb 20;348(8):727–734. [PubMed] []
26. Centers for Disease Control and Prevention. Multistate outbreak of fungal meningitis and other infections. Centers for Disease Control and Prevention. 2013 October 23. http://www.cdc.gov/hai/outbreaks/meningitis.html. Accessed April 1, 2014. []
27. US Food and Drug Administration. 2006 Limited Survey of Compounded Drug Products. 2010 March 22. http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/ucm204237.htm. Accessed March 14, 2013. []
28. US Food and Drug Administration. FDA Form 483: inspectional observations. 2012 http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ORA/ORAElectronicReadingRoom/UCM325980.pdf. Accessed March 14, 2013. []
29. US Food and Drug Administration. Compounding Quality Act, Title I of the Drug Quality and Security Act of 2013. 2014 January 10. http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/pharmacycompounding/default.htm. Accessed April 1, 2014. []
5. Kenna HA, Poon AW, de los Angeles CP, Koran LM. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci2011 Oct;65(6):549–560. [PubMed[]

6. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc2006 Oct;81(10):1361–1367. [PubMed[]

7. Patten SB, Neutel CI. Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. Drug Saf2000 Feb;22(2):111–122. [PubMed[]

8. Pereira RM, Carvalho JF, Canalis E. Glucocorticoid-induced osteoporosis in rheumatic diseases. Clinics (Sao Paulo) 2010;65(11):1197–1205. [PMC free article] [PubMed[]

9. Lansang MC, Hustak LK. Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleve Clin J Med2011 Nov;78(11):748–756. [PubMed[]

10. Benzon HT, Gissen AJ, Strichartz GR, Avram MJ, Covino BG. The effect of polyethylene glycol on mammalian nerve impulses. Anesth Analg1987 Jun;66(6):553–559. [PubMed[]

11. Craig DB, Habib GG. Flaccid paraparesis following obstetrical epidural anesthesia: possible role of benzyl alcohol. Anesth Analg1977 Mar-Apr;56(2):219–221. [PubMed[]

12. Ahadian FM, McGreevy K, Schulteis G. Lumbar transforaminal epidural dexamethasone: a prospective, randomized, double-blind, dose-response trial. Reg Anesth Pain Med2011 Nov-Dec;36(6):572–578. [PubMed[]

13. Dreyfuss P, Baker R, Bogduk N. Comparative effectiveness of cervical transforaminal injections with particulate and nonparticulate corticosteroid preparations for cervical radicular pain. Pain Med2006 May-Jun;7(3):237–242. [PubMed[]

14. Somayaji HS, Saifuddin A, Casey AT, Briggs TW. Spinal cord infarction following therapeutic computed tomography-guided left L2 nerve root injection. Spine (Phila Pa 1976) 2005 Feb 15;30(4):E106–E108. [PubMed[]